What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease?

Neuropathology

Volumn 28, Issue 4, 2008, Pages 351-365

  Armstrong, Richard A ^a   Lantos, Peter L ^b   Cairns, Nigel J ^c  

^a ASTON UNIVERSITY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cellular inclusion; Disease pathogenesis; Gene mutation; Molecular composition; Neurodegenerative disease; Protein aggregate

Indexed keywords

AMYLOID BETA PROTEIN; PRION PROTEIN; SYNUCLEIN;

ALZHEIMER DISEASE; CELL DEGENERATION; CELL INCLUSION; CELL LOSS; CELL STRUCTURE; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DISEASE ACTIVITY; GENE MUTATION; HUMAN; NERVE CELL; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; REVIEW; TAUOPATHY;

ALPHA-SYNUCLEIN; AMYLOID BETA-PROTEIN; ANIMALS; HUMANS; INCLUSION BODIES; NEURODEGENERATIVE DISEASES; PRPC PROTEINS; PRPSC PROTEINS; SENILE PLAQUES; TAU PROTEINS;

EID: 44849083256     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2008.00916.x     Document Type: Review

References (151)

1. Graeber MB, Kosel S, Egensperger R et al. Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis. Neurogenetics 1997 1:73 80.
2. Forstl H. The Lewy body variant of Alzheimer's disease: clinical, pathophysiological and conceptual issues. Eur Arch Psych Clin Neurol 1999 249:64 67.
3. Duckett S, Stern J. Origins of the Creutzfeldt and Jakob concept. J Hist Neurosci 1999 8:21 34.
4. Armstrong RA, Lantos PL, Cairns NJ. Overlap between neurodegenerative disorders. Neuropathology 2005 25:111 124.
5. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984 122:1131 1135.
6. Schulz-Schaeffer WJ, Giese A, Windl O, Kretschmar HA. Polymorphism at codon 129 of the prion protein gene determines cerebellar pathology in Creutzfeldt-Jakob disease. Clin Neuropathol 1996 15:353 357.
7. McKeith IG, Galasko D, Kosaka K et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996 47:1113 1124.
8. Love S, Saitoh T, Quijada S, Cole GM, Terry RD. Ubiquitin and tau immunoreactivity of neurofibrillary tangles, Pick bodies and Lewy bodies. J Neuropathol Exp Neurol 1988 47:393 405.
9. Ikeda K. Basic pathology of corticobasal degeneration. Neuropathology 1997 17:127 133.
10. Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomology. Brain 1994 117:235 243.
11. Chartier-Harlin M, Crawford F, Houlden H et al. Early onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 1991 353:844 846.
12. Goate R, Chartier-Harlin M, Mullan M et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991 349:704 706.
13. Sherrington R, Rogaev EI, Liang Y et al. Cloning of a gene bearing missense mutations in early onset familial Alzheimer's disease. Nature 1993 375:754 760.
14. Levy-Lahad E, Wasco W, Poorkaj P et al. Candidate gene for chromosome 1 familial Alzheimer's disease locus. Science 1995 269:973 977.
15. Reed LA, Wszolek ZK, Hutton M. Phenotypic correlates in FTDP-17. Neuropathol Aging 2001 22:89 107.
16. Nussbaum RL, Polymeropoulos MH. Genetics of Parkinson's disease. Hum Mol Genet 1997 6:1687 1691.
17. West AB, Moore DJ, Biskup S et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 2005 102:16842 16847.
18. Neumann M, Muller V, Gorner K, Kretzschmar HA, Haass C, Kahle PJ. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Parkinson's disease. Acta Neuropathol 2004 107:489 496.
19. Haupt M, Kurz A, Pollman S, Romero B. Comparison of the severity of neuropathological changes in familial and sporadic Alzheimer's disease. J Neurol 1992 239:248 250.
20. Nochlin D, Van Belle G, Bird TD, Sumi SM. Comparison of the severity of neuropathological changes in familial and sporadic Alzheimer's disease. Alzheimer Dis Assoc Disord 1993 7:212 222.
21. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992 256:184 185.
22. Miller DL, Papayannopoulos IA, Styles J et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 1993 301:41 52.
23. Roher AE, Lowenson JD, Clarke S et al. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 1993 268:3072 3073.
24. Yamaguchi H, Ishiguro K, Sugihara S et al. Presence of apolipoprotein e on extracellular neurofibrillary tangles and on meningeal blood vessels precedes the Alzheimer β-amyloid deposition. Acta Neuropathol 1994 88:413 419.
25. Desai PP, Ikonomovic MD, Abrahamson EE et al. Apolipoprotein D is a component of compact but not diffuse amyloid-beta plaques in Alzheimer's disease temporal cortex. Neurobiol Dis 2005 20:574 582.
26. Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, Budka H. Coexistence of Alzheimer type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol 1998 96:116 122.
27. Schmidt ML, Lee VMY, Trojanowski JQ. Comparative epitope analysis of neuronal cytoskeletal proteins in Alzheimer's disease senile plaque neurites and neuropil threads. Lab Invest 1991 64:352 357.
28. Krzanowski JJ. Microglia and immune activation in Alzheimer's disease. J Flor MA 1993 80:267 270.
29. Akiyama H, Yamada T, Kawanata T, McGeer PL. Association of amyloid-P component with complement proteins in neurologically diseases brain tissue. Brain Res 1991 548:349 352.
30. Kimura M, Arai H, Takahashi T, Iwamoto N. Amyloid-P component like immunoreactivity in β/A4-immunoreactive deposits in Alzheimer-type dementia brains. J Neurol 1994 241:170 174.
31. Cummings BJ, Su JH, Cotman CW, White R, Russell MJ. β-amyloid accumulation in aged canine brain: a model of early plaque formation in Alzheimer's disease. Neurobiol Aging 1993 14:547 560.
32. Verga L, Frangione B, Tagliavini F, Giaccone G, Migheli A, Bugiani O. Alzheimer's and Down's patients: cerebral preamyloid deposits differ ultrastructurally and histochemically from the amyloid of senile plaques. Neurosci Lett 1989 105:294 299.
33. Eikelenboom P, Zhan SS, van Gool WA, Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci 1994 15:447 450.
34. Tabaton M, Cammarata S, Mancardi G et al. Ultrastructural localisation of β, tau and ubiquitin epitopes in extracellular neurofibrillary tangles. Proc Natl Acad Sci USA 1991 88:2098 2102.
35. Smith MA, Taneda S, Richey PL. et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 1994 91:5710 5714.
36. Saito Y, Ruberu NN, Sawabe M et al. Staging of agyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol 2004 63:911 918.
37. Adams LA, Munoz DG. Differential incorporation of processes derived from different classes of neurons into senile plaques in Alzheimer's disease. Acta Neuropathol 1993 86:365 370.
38. Struble RG, Powers RE, Casanova MF, Kitt CA, Brown EC, Price DL. Neuropeptidergic systems in plaques of Alzheimer's disease. J Neuropath Exp Neurol 1987 46:567 584.
39. Ferrer I, Freixas M, Blanco R, Carmona M, Puig B. Selective PrP-like protein, doppel immunoreactivity in dystrophic neurites of senile plaques in Alzheimer's disease. Neuropathol Appl Neurobiol 2004 30:329 337.
40. Armstrong RA, Cairns NJ, Ironside JW, Lantos PL. Quantification of vacuolation ("spongiform change"), surviving neurones and prion protein deposition in eleven cases of variant Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol 2002 28:129 135.
41. Armstrong RA, Lantos PL, Ironside JW, Cairns NJ. Differences in the density and distribution of florid and diffuse plaques in variant Creutzfeldt-Jakob disease (vCJD). Clin Neuropathol 2003 22:209 214.
42. Rangon CM, Haik S, Faucheux BA et al. Different chromagranin immunoreactivity between prion and Aβ amyloid plaques. Neuroreport 2003 14:755 758.
43. Freixes M, Puig B, Rodriguez A, Torrejon-Escribon B, Blanco R, Ferrer I. Clusterin solubility and aggregation in Creutzfeldt-Jakob disease. Acta Neuropathol 2004 108:295 301.
44. Graner E, Mercadante AF, Zanata SM et al. Cellular prion protein binds laminin and mediates neuritogenesis. Brain Res Mol Brain Res 2000 76:85 92.
45. Dickson DW. Neuropathological differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999 246 (Suppl 2 6 15.
46. Morris HR, Baker M, Yasojima K et al. Analysis of tau haplotypes in Pick's disease. Neurology 2002 59:443 445.
47. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991 541:163 166.
48. Perry G, Siedlak SL, Richey P et al. Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer's disease. J Neurol 1991 11:3679 3683.
49. Bancher C, Grundke-Iqbal I, Iqbal K, Fried VA, Smith HT, Wisniewski HM. Abnormal phosphorylation of tau precedes ubiquitination in neurofibrillary pathology of Alzheimer's disease. Brain Res 1991 539:11 18.
50. Arima K, Nakamura M, Sunohara N et al. Immunohistochemical and ultrastructural characterisation of neuritic clusters around ghost tangles in the hippocampal formation in progressive supranuclear palsy. Acta Neuropathol 1999 97:565 576.
51. Yamaguchi H, Nakazato Y, Shoji M et al. Secondary deposition of beta amyloid within extracellular tangles in Alzheimer-type dementia. Am J Pathol 1991 138:699 705.
52. Itagaki S, Akiyama H, Saito H, McGeer PL. Ultrastructural localization of complement membrane attack complex (MAC) -like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res 1994 645:78 84.
53. Perry G. Neuritic plaques in Alzheimer's disease originate from neurofibrillary tangles. Med Hypotheses 1993 40:257 258.
54. Bayer TA, Jakala P, Hartmann T et al. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta amyloid plaque cores. Neurosci Lett 1999 266:213 216.
55. Wakabayashi K, Takahashi H. Cellular pathology in multiple system atrophy. Neuropathology 2006 26:338 345.
56. Arima K, Hirai S, Sunohara N et al. Cellular co-localisiation of phosphorylated tau and NACP/alpha-synuclein epitopes in Lewy bodies in sporadic Parkinsons's disease and in dementia with Lewy bodies. Brain Res 1999 843:53 61.
57. Iwatsubo T, Yamaguchi H, Fujimuro M et al. Purification and characterisation of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol 1996 148:1517 1529.
58. Alim MA, Hossain MS, Arima K et al. Tubulin seeds alpha-synuclein fibril formation. J Biol Chem 2002 277:2112 2117.
59. Brion JP, Couk AM. Cortical and brain stem type Lewy bodies are immunoreactive for the cyclin dependent kinase-5. Am J Pathol 1995 147:1465 1476.
60. Fukuda T, Tanaka J, Watabe K, Numoto RT, Minamitani M. Immunohistochemistry of neuronal inclusions in the cerebral cortex and brain stem in Lewy body dementia. Acta Pathol Jpn 1993 43:545 551.
61. Lowe J, Mayer RJ, Landon M. Ubiquitin in neurodegenerative diseases. Brain Pathol 1993 3:55 65.
62. Gai WP, Blumbergs PC, Blessing WW. Microtubule-associated protein-5 is a component of Lewy bodies and Lewy body neurites in the brainstem and forebrain regions affected in Parkinson's disease. Acta Neuropathol 1996 91:78 81.
63. Hayashi S, Wakabayashi K, Iwanaga K et al. Pick's disease: selective occurrence of apolipoprotein E immunoreactive Pick bodies in the limbic system. Acta Neuropathol 1998 95:1 4.
64. Kimura M, Ikeda K, Takamatsu J et al. Identification of advanced glycylation end-products of the Maillard reaction in Pick's disease. Neurosci Lett 1996 279:95 98.
65. Amouyel P, Vidal O, Launay JM, Laplanche JL. The apolipoprotein-E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. Lancet 1994 344:1315 1318.
66. Nakamura Y, Takeda M, Yoshimi K et al. Involvement of clathrin light chains in the pathology of Pick's disease: implications for impairment of axonal transport. Neurosci Lett 1994 180:25 28.
67. Singhrao SK, Neal JW, Gasque P, Morgan BP, Newman GR. Role of complement in the etiology of Pick's disease. J Neuropathol Exp Neurol 1996 55:578 593.
68. Nakamura S, Kawamoto Y, Nakano S, Akiguchi I, Kimura J. Cyclin-dependent kinase 5 and mitogen activated protein kinase in glial cytoplasmic inclusions in multiple system atrophy. J Neuropathol Exp Neurol 1998 57:690 698.
69. Izumiyama Y, Ikeda K, Oyanagi S. Extracellular or ghost Pick bodies and their lack of tau immunoreactivity: a histological, immunohistochemical and electron microscope study. Acta Neuropathol 1994 87:277 283.
70. Nasreddine ZS, Logimov M, Clark LN et al. From genotype to phenotype: a clinical pathological and biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-17) caused by the P300L tau mutation. Ann Neurol 1999 45:705 715.
71. Foster NL. Fronto-temporal dementia with parkinsonism linked to chromosome 17 (FTDP-17): a clinician's guide. Neurologist 1999 5:213 221.
72. Ikeda K, Akiyama H, Kondo H et al. Thorn-shaped atrocytes: possible secondarily induced tau-positive glial fibrillary tangles. Acta Neuropathol 1995 90:620 625.
73. Feany MB, Dickson DW. Widespread cytoskeletal pathology characterises corticobasal degeneration. Am J Pathol 1995 146:1388 1396.
74. Yamada T, McGeer PL, McGeer EG. Appearance of paired nucleated tau positive glia in patients with progressive supranuclaer palsy brain tissue. Neurosci Lett 1992 135:99 102.
75. Takeda A, Arai N, Komori T, Iseki E, Kato S, Oda M. Tau immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 1997 234:63 66.
76. Piao YS, Hayashi S, Hasegawa M et al. Co-localisation of α-synuclein and phosphorylated tau and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration. Acta Neuropathol 2001 101:285 293.
77. Nakamura S, Kawamoto Y, Nakano S, Akiguchi I. Expression of the endocytosis regulatory proteins Rab5 and Rabaptin 5 in glial cytoplasmic inclusions from brains with multiple system atrophy. Clin Neuropath 2000 19:51 56.
78. Cairns NJ, Atkinson PF, Hanger DP, Anderton BH, Daniel SE, Lantos PL. Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease. Neurosci Lett 1997 230:49 52.
79. Gai WP, Power JHT, Blumbergs PC, Culvenor JG, Jensen PH. Alpha-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components. J Neurochem 1999 73:2093 2100.
80. Bigio EH, Lipton AM, White CL, Dickson DW, Hirano A. Frontotemporal dementia and motor neurone degeneration with neurofilament inclusion bodies: additional evidence for overlap between FTD and ALS. Neuropathol Appl Neurobiol 2003 29:239 253.
81. Cairns NJ, Perry RH, Jaros E et al. Patients with a novel neurofilamentopathy: dementia with neurofilament inclusions. Neurosci Lett 2003 341:177 180.
82. Josephs KA, Holton JL, Rossor MN et al. Neurofilament inclusion body disease: a new proteinopathy? Brain 2003 126:2291 2303.
83. Armstrong RA, Cairns NJ. Topography of α-internexin-positive neuronal aggregates in 10 patients with neuronal intermediate filament inclusion disease. Eur J Neurol 2006 13:528 532.
84. Armstrong RA, Kerty E, Skullerud K, Cairns NJ. Neuropathological changes in ten cases on neuronal intermediate filament inclusion disease (NIFID): a study using a-internexin immunohistochemistry and principal components analysis. J Neural Transm 2006 113:1207 1215.
85. Neumann M, Sampathu DM, Kwong LK et al. Ubiquinated TDP-43 in frontotemporal lobar degeneration and amylotrophic lateral scerosis. Science 2006 314:130 133.
86. Armstrong RA, Cairns NJ, Lantos PL. Are pathological lesions in neurodegenerative disorders the cause or the effect of the degeneration? Neuropathology 2002 22:114 127.
87. Armstrong RA, Cairns NJ, Ironside JW. Size frequency distributions of the florid prion protein aggregates in variant Creutzfeldt-Jakob disease follow a power-law function. Neuro Sci 2006 27:104 109.
88. Armstrong RA, Cairns NJ, Ironside JW, Lantos PL. Size frequency distributions of prion protein (PrP) aggregates in variant Creutzfeldt-Jakob disease. J Neural Transm 2005 112:1565 1573.
89. Delaere P, Duyckaerts C, He Y, Piette F, Hauw JJ. Subtypes and differential laminar distribution of β/A4 deposits in Alzheimer's disease: relationship with the intellectual status of 26 cases. Acta Neuropathol 1991 81:328 335.
90. Greenberg BD. The COOH-terminus of the Alzheimer amyloid Aβ peptide: differences in length influence the process of amyloid deposition in Alzheimer brain, and tell us something about relationships among parenchymal and vessel-asssociated amyloid deposits. Amyloid 1995 21:195 203.
91. Armstrong RA. β-amyloid plaques: stages in life history or independent origin? Dement Geriatr Cogn Disord 1998 9:227 238.
92. Delacourte A, Sergeant N, Champain D et al. Nonoverlapping but synergetic tau and amyloid precursor protein pathologies in sporadic Alzheimer's disease. Neurology 2002 59:398 407.
93. Mann DMA, Brown SMP, Owen F, Baba M, Iwasubo T. Amyloid beta protein (Aβ) deposition in dementia with Lewy bodies: predominance of Aβ42/43 and a paucity of Aβ40 compared with sporadic Alzheimer's disease. Neuropathol Appl Neurobiol 1998 24:187 194.
94. Goedert M, Spillantini MG, Serpell LC et al. From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases. Philos Trans R Soc Lond B Biol Sci 2001 356:213 227.
95. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple systems atrophy with Parkinsons's disease and dementia with Lewy bodies. Neurosci Lett 1998 251:205 208.
96. Wakabayashi K, Tanji K, Mori F, Takahashi H. The Lewy body in Parkinsons's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007 27:506 518.
97. Goate AM. Monogenetic determinants of Alzheimer's disease: amyloid precursor protein mutations. Cell Mol Life Sci 1998 54:897 901.
98. Berkenbosch F, Refolo LM, Friedrich VL, Casper D, Blum M, Robakis NK. The Alzheimer's amyloid precursor protein is produced by type 1 astrocytes in primary cultures of rat microglia. J Neurosci Res 1990 25:431 440.
99. Octave JN. The amyloid peptide precursor in Alzheimer's disease. Acta Neurol Belg 1995 95:197 209.
100. Kim JR, Muresan A, Lee KYC, Murphy RM. Urea modulation of beta-amyloid fibril growth: experimental studies and kinetic models. Protein Sci 2004 13:2888 2898.
101. Podlisny MB, Tolan DR, Selkoe DJ. Homology of amyloid Beta protein precursor in monkey and human supports a primate model for Beta amyloidosis in Alzheimer's disease. Am J Pathol 1991 138:1423 1433.
102. Steiner H, Capell A, Leimer U, Haass C. Genes and mechanisms involved in beta-amyloid generation and Alzheimer's disease. Eur Arch Psych Clin Neurol 1999 249:266 270.
103. Zatti G, Burgo A, Giacomello M et al. Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatues calcium levels. Cell Calcium 2006 39:539 550.
104. Francis YI, Stephanou A, Latchman DS. CREB-binding protein activation by presenilin 1 but not by its M146L mutant. Neuroreport 2006 17:917 921.
105. Sudoh S, Kawamura Y, Sato K et al. Presenilin-1 mutations linked to FAD increase the intracellular levels of amyloid beta protein 1-42 and its n-terminally truncated variant (s) which are generated at distinct sites. J Neurochem 1998 71:1535 1543.
106. Goldfarb LG, Brown P, Cervenakova L, Gajdusek DC. Genetic analysis of Creutzfeldt-Jakob disease and related disorders. Philos Trans R Soc Lond B Biol Sci 1994 343:379 384.
107. Armstrong RA, Cairns NJ, Lantos PL. Quantification of the vacuolation ("spongiform change") and prion protein deposition in 11 patients with sporadic Creutzfeldt-Jakob disease. Acta Neuropathol 2001 102:591 596.
108. Armstrong RA, Cairns NJ, Ironside JW, Lantos PJ. Spatial correlations between the vacuolation, prion protein deposition, and surviving neurons in variant Creutzfeldt-Jakob disease in variant Creutzfeldt-Jakob disease. J Neural Transm 2003 110:1303 1311.
109. Parchi P, Giese A, Capillari S et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analyis of 300 subjects. Ann Neurol 1999 46:224 233.
110. MacDonald ST, Sutherland K, Ironside JW. Prion protein genotype and pathological phenotype studies in sporadic Creutzfeldt-Jakob disease. Neuropath Appl Neurobiol 1996 22:285 292.
111. Pickering-Brown SM, Richardson AMT, Snowden JS et al. Inherited frontotemporal dementia in nine British families associated with intronic mutations of the tau gene. Brain 2002 125:732 751.
112. Lippa CF, Zhukareva V, Kawari T et al. Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation. Ann Neurol 2000 48:850 858.
113. Lee VM-Y, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Ann Rev Neurosci 2001 24:1121 1159.
114. Vogelsberg-Ragaglia V, Bruce J, Richter-Landsberg C et al. Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells. Mol Biol Cell 2000 11:4093 4104.
115. Goedert M, Spillantini MG. Tau gene mutations and neurodegeneration. Biochem Soc Symp 2001 67:59 71.
116. Higgins JJ, Adler RL, Loveless JM. Mutational analysis of the tau gene in progressive supranuclear palsy. Neurology 1999 53:1421 1424.
117. Armstrong RA, Lantos PL, Cairns NJ. Spatial patterns of α-synuclein positive glial cytoplasmic inclusions in multiple system atrophy. Mov Disord 2004 19:109 112.
118. Forloni G, Bertain I, Catella AM, Thaler F, Invernizzi R. Alpha-synuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann Neurol 2000 47:632 640.
119. Masliah E, Rockenstein E, Veinbergs I. et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000 287:1265 1269.
120. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006 59:449 458.
121. Van de Warrenburg BPC, Lammens M et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001 56:555 557.
122. Hoenicka J. Genes in Alzheimer's disease. Rev Neurol 2006 42:302 305.
123. Forman MS, Trojanowski JQ, Lee VM-Y. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004 10:1055 1063.
124. Mullan M, Crawford F. Genetic and molecular advances in Alzheimer's disease. Trends Neurosci 1993 16:398 403.
125. Wisniewski T, Ghiso J, Frangione B. Alzheimer's disease and soluble Aβ. Neurobiol Aging 1994 15:143 152.
126. Maruyama K, Kawamura Y, Asada H, Ishuira S, Obata K. Cleavage at the N-terminal site of Alzheimer amyloid β/A4 protein is essential for its secretion. Biochem Biophys Res Commun 1994 202:1517 1523.
127. Wallace WC, Bragin V, Robakis NK et al. Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. Brain Res Mol Brain Res 1991 10:173 178.
128. Banati RB, Gehrmann J, Czech C et al. Early and rapid de novo synthesis of Alzheimer βA4-amyloid precursor protein (APP) in activated microglia. Glia 1993 9:199 210.
129. Stephenson DT, Rash K, Clemens JA. Amyloid precursor protein accumulates in regions of neurodegeneration following focal cerebral ischaemia in the rat. Brain Res 1992 593:128 135.
130. Beeson JG, Shelton ER, Chan HW, Gage FH. Age and damage induced changes in amyloid precursor protein immunohistochemistry in the rat brain. J Comp Neurol 1994 342:69 77.
131. Regland B, Gottfries CG. The role of amyloid β-protein in Alzheimer's disease. Lancet 1992 340:467 469.
132. Drouet B, Pincon-Raymond M, Chambaz J, Pillot T. Molecular basis of Alzheimer's disease. Cell Mol Life Sci 2000 57:705 715.
133. Mochizuki A, Peterson JW, Mufson EJ, Trapp BD. Amyloid load and neural elements in Alzheimer's disease and nondemented individuals with high amyloid plaque density. Exp Neurol 1996 142:89 102.
134. Armstrong RA. Correlations between the morphology of diffuse and primitive β-amyloid (Aβ) deposits and the frequency of associated cells in Down's syndrome. Neuropath Appl Neurobiol 1996 22:527 530.
135. Armstrong RA. Diffuse β-amyloid (Aβ) deposits and neurons: in situ secretion or diffusion of Aβ? Alzheimers Rep 2001 3:289 294.
136. Munoz DG. Chromagranin A-like immunoreactive neuritis are major constituents of senile plaques. Lab Invest 1991 64:826 832.
137. Gertz HJ, Kruger H, Patt S, Cervos-Navarro J. Tangle-bearing neurons show more extensive dendritic trees than tangle-free neurons in area CA1 of the hippocampus in Alzheimer's disease. Brain Res 1991 548:260 266.
138. Torack RM, Miller JW. Immunoreactive changes resulting from dopaminergic denervation of the dentate gyrus of the rat hippocampal formation. Neurosci Lett 1994 169:9 12.
139. Newell KL, Boyer P, Gomez-Tortosa E et al. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. J Neuropath Exp Neurol 1999 58:1263 1268.
140. Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 2000 11:211 213.
141. Yazdani U, German DC, Liang CL, Manzino L, Sonsalla PK, Zeevalk GD. Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4- phenylpyridinium (MPP (+). Exp Neurol 2006 200:172 183.
142. Bergmann M, Kulchelmeister K, Schmid KW, Kretzschmar HA, Schroder R. Different variants of frontotemporal dementia: a neuropathological and immunohistochemical study. Acta Neuropathol 1996 92:170 179.
143. Wisniewski HM, Merz PA, Iqbal K. Ultrastructure of paired helical filaments of Alzheimer's neurofibrillary tangle. J Neuropath Exp Neurol 1984 43:643 656.
144. Uchihara T, Duyckaerts C, Lazarini F et al. Inconstant apolipoprotein (Apo E) - like immunoreactivity in amyloid beta deposits: relationship with Apo E genotype in aging brain and Alzheimer's disease. Acta Neuropathol 1996 92:180 185.
145. Strittmatter WJ, Wiesgraber KH, Huang DY et al. Binding of human apolipoprotein E to synthetic amyloid-β peptide: isoform specific effects and implications for late-onset Alzheimer's disease. Proc Natl Acad Sci USA 1993 90:8098 8102.
146. Armstrong RA. Classic β-amyloid deposits cluster around large diameter blood vessels rather than capillaries in sporadic Alzheimer's disease. Curr Neurovasc Res 2006 3:289 294.
147. Benzing WC, Mufson EJ. Apolipoprotein E immunoreactivity within neurofibrillary tangles: relationship to tau and paired helical filaments in Alzheimer's disease. Exp Neurol 1995 132:162 171.
148. Iseki E, Marui W, Akiyama H, Ueda K, Kosaka K. Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using alpha-synuclein immunohistochemistry. Neurosci Lett 2000 286:69 73.
149. Swerdlow RH, Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses 2004 63:8 20.
150. Kalaria RN, Bhatti SU, Perry G, Lust WD. The amyloid precursor protein in ischaemic brain injury and chronic hypoperfusion. Proceedings of the 7th Inter Study Group. Pharm Mem Dis Assoc Aging 1993:291 294.
151. Carroll BJ. Ageing, stress and the brain. Endocrine facets of ageing. Novartis Found Symp 2002 242:26 36.